SELLAS Life Sciences Group, Inc.

NASDAQ:SLS

Biotechnology

Healthcare
$17.95 +4.02%

+$0.31 today

Market cap
$3.66B
Beta
2.53
P/E (TTM)
-47.3
EPS (TTM)
-$0.17
52W Low $1.39High $9.51

Volume 35.53M

Average 7.79M

Returns on capital

SELLAS Life Sciences Group, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-37.9%

avg -314.2%

ROIC

-39.3%

avg -125.9%

ROA

-34.3%

avg -142.7%

Analysis

ROA is currently the strongest return metric at -34.3% versus its period average of -142.7%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Angelos Stergiou

Founder, President, Chief Executive Officer & DirectorUSD 1.07M50——

Dragan Cicic

Senior Vice President & Chief Development OfficerUSD 662.73K63557.80K0.39%

John Thomas Burns

Senior Vice President & Chief Financial OfficerUSD 630.59K41554.33K0.39%

Andrew Elnatan

Senior Vice President of Regulatory Affairs, CMC & Quality————

Stacy Yeung

VP, General Counsel & Corporate Secretary————

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Jan 7, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

1

$100,806.00

Sells

0

$0.00

Net Transaction Value

+$100,806.00

Net buying

Most Active

Kalin Katherine Bach

1 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Nov 19, 25

Kalin Katherine Bach

Direct

Buy$100.8K

Summary

Insiders reported 1 buys worth $100,806.00 and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $100,806.00. Kalin Katherine Bach was the most active insider with 1 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A1 analysts
RevenueN/AN/AN/A
N/A1 analysts
Net IncomeN/AN/AN/A
N/A1 analysts
EBITN/AN/AN/A
N/A1 analysts

Analysis

Analysis will appear once historical growth or forward estimates are available for this company.

Competitors

Who does SELLAS Life Sciences Group, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about SLS's management, answered from reported figures.

Who manages SLS?

SELLAS Life Sciences Group, Inc. (SLS) lists 5 active executives. The top listed executive is Angelos Stergiou, Founder, President, Chief Executive Officer & Director.

Are SLS insiders buying or selling?

Recent insider activity shows net buying of $8.86M.